These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16104040)

  • 1. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
    Tefferi A; Dingli D; Li CY; Dewald GW
    Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
    Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
    Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
    Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
    Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
    Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
    Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Simonitsch-Klupp I; Gisslinger H; Zojer N; Ludwig H
    Cancer; 2006 Dec; 107(12):2801-6. PubMed ID: 17103442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
    Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
    Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.
    Arora B; Sirhan S; Hoyer JD; Mesa RA; Tefferi A
    Br J Haematol; 2005 Jan; 128(1):42-8. PubMed ID: 15606548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.
    Dingli D; Grand FH; Mahaffey V; Spurbeck J; Ross FM; Watmore AE; Reilly JT; Cross NC; Dewald GW; Tefferi A
    Br J Haematol; 2005 Jul; 130(2):229-32. PubMed ID: 16029451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for leukemic transformation in patients with primary myelofibrosis.
    Huang J; Li CY; Mesa RA; Wu W; Hanson CA; Pardanani A; Tefferi A
    Cancer; 2008 Jun; 112(12):2726-32. PubMed ID: 18404742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
    Cervantes F; Barosi G
    Semin Oncol; 2005 Aug; 32(4):395-402. PubMed ID: 16202685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
    Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP
    Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional cytogenetics in myelofibrosis: literature review and discussion.
    Hussein K; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
    Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
    Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
    Tefferi A; Huang J; Schwager S; Li CY; Wu W; Pardanani A; Mesa RA
    Cancer; 2007 May; 109(10):2083-8. PubMed ID: 17407134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
    Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
    Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.
    Tefferi A; Mesa RA; Schroeder G; Hanson CA; Li CY; Dewald GW
    Br J Haematol; 2001 Jun; 113(3):763-71. PubMed ID: 11380468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in the long arm of chromosome 3 (3q) in malignant myeloid hemopathies. A study of 10 cases].
    Sancho JM; Granada I; Ribera JM; Batlle M; Hernández JA; Navarro JT; Fernández F; Millá F; Feliu E
    Med Clin (Barc); 1999 Apr; 112(13):499-502. PubMed ID: 10353117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.